Lupin receives approval from U.S. FDA for Desvenlafaxine Extended-Release Tablets 25 mg

Global pharma major Lupin Limited (Lupin) has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Desvenlafaxine Extended-Release Tablets, 25 mg to market a generic equivalent of Pristiq® Extended-Release Tablets, 25 mg of PF PRISM C.V. The product will be manufactured at Lupin's facility in Goa, India.

Desvenlafaxine Extended-Release Tablets, 25 mg (RLD Pristiq®) had estimated annual sales of USD 14 million in the U.S. (IQVIA MAT December 2021).

Shares of Lupin Limited was last trading in BSE at Rs. 772.35 as compared to the previous close of Rs. 773.70. The total number of shares traded during the day was 49690 in over 2370 trades.

The stock hit an intraday high of Rs. 779.40 and intraday low of 765.80. The net turnover during the day was Rs. 38415983.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Desvenlafaxine ExtendedRelease Tablets ANDA Approval Pristiq